Adsorbent

Patent metadata

Field	Value
Publication number	US-2015297820-A1
Application number	US-201314427247-A
Country	US
Kind code	A1
Filing date	Sep 9, 2013
Priority date	Sep 10, 2012
Publication date	Oct 22, 2015
Grant date	—

Abstract

The objective of the present invention is to obtain an adsorbent having high adsorption capacity and high strength comprising porous cellulose beads obtained without using an auxiliary material which is highly toxic and corrosive and without a cumbersome and industrially adverse step. The present invention is characterized by immobilizing a ligand onto porous cellulose beads obtained by mixing a cold alkaline aqueous solution and cellulose powder as a raw material to prepare a cellulose dispersion and bringing the cellulose dispersion into contact with a coagulating solvent.

First claim

1 . An adsorbent, comprising:
porous cellulose beads obtained by a process comprising mixing a cold alkaline aqueous solution and cellulose powder as a raw material to prepare a cellulose dispersion, and bringing the cellulose dispersion into contact with a coagulating solvent.

2 . The adsorbent according to claim 1 , further comprising:
an affinity ligand.

3 . The adsorbent according to claim 2 , wherein the affinity ligand is introduced at an amount of not less than 1 mg and not more than 500 mg per 1 mL of the adsorbent.

4 . The adsorbent according to claim 2 , wherein the affinity ligand is protein A.

5 . The adsorbent according to claim 4 , wherein the protein A has an alkaline resistance.

6 . The adsorbent according to claim 5 , wherein the protein A is an orientation-controlled protein A.

7 . The adsorbent according to claim 1 , wherein the adsorbent adsorbs IgG, and 5% DBC of IgG for residence time of 3 minutes is not less than 60 g/L.

8 . The adsorbent according to claim 1 , wherein the adsorbent adsorbs IgG, and 5% DBC of IgG for residence time of 6 minutes is not less than 70 g/L.

9 . The adsorbent according to claim 1 , further comprising:
dextran sulfate as a ligand.

10 . The adsorbent according to claim 1 , wherein the adsorbent adsorbs LDL cholesterol and has an adsorption capacity of LDL cholesterol of not less than 7 g/L.

11 . The adsorbent according to claim 1 , wherein a temperature of the cold alkaline aqueous solution is not more than 20° C.

12 . The adsorbent according to claim 1 , wherein a cellulose concentration in the cellulose dispersion is not less than 1 wt % and not more than 10 wt %.

13 . The adsorbent according to claim 1 , wherein an alkaline concentration in the alkaline aqueous solution is not less than 5 wt % and not more than 15 wt %.

14 . A method for a purification, comprising:
subjecting a substance to a purification employing the adsorbent according to claim 1 .

15 . A method for a treatment, comprising:
subjecting a substance to a treatment employing the adsorbent according to claim 1 .

16 . The adsorbent according to claim 2 , further comprising:
dextran sulfate as a ligand.

17 . The adsorbent according to claim 3 , wherein the affinity ligand is protein A.

18 . A method of producing an adsorbent, comprising:
mixing a cold alkaline aqueous solution and cellulose powder as a raw material to prepare a cellulose dispersion; and bringing the cellulose dispersion into contact with a coagulating solvent to obtain a porous cellulose bead.

19 . The method according to claim 18 , wherein a cellulose concentration in the cellulose dispersion is not less than 1 wt % and not more than 10 wt %.

20 . The method according to claim 18 , wherein an alkaline concentration in the alkaline aqueous solution is not less than 5 wt % and not more than 15 wt %.

Assignees

• Kaneka Corp

Inventors

• Kawai Yoshikazu
• Morio Ken-Ichiro
• Konike Fuminori
• Watanabe Kana
• Suzuki Yasuyuki
• Hirano Masaru

Classifications

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P7/08

  Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04) · CPC title

• C08L1/02

  Cellulose; Modified cellulose · CPC title